However, it revealed thereafter that the DC plus IFNγ treatment still not enough to elicit effective clinical outcomes against malignant tumor in the large size or progressive stage and metastatic tumors in which DCs and IFNγ is difficult to be directly injected. The gene discussed is IFNG; the disease is metastatic neoplasm.